Clear cell renal carcinoma

This study looked at whether the drug cabozantinib can help people with advanced kidney cancer that got worse after initial treatment with immunotherapy. 127 participants received cabozantinib as a second-line therapy. The main goal was to see how many patients experienced tumor …

This pilot study is testing whether a rapid, timed sequence of different drugs can improve outcomes for people with advanced or inoperable clear cell kidney cancer. Participants first receive cabozantinib, then a combination of two immunotherapies (ipilimumab and nivolumab), foll…

This phase 2 trial is testing a new drug called cadonilimab (AK104), either alone or combined with axitinib, as a first treatment for advanced or metastatic kidney cancer. The study includes two parts: one testing different doses of cadonilimab alone in various kidney cancer type…

This study tested a combination of two experimental treatments for people with advanced kidney cancer that cannot be removed by surgery. The first is Pexa-Vec, a modified virus designed to infect and destroy cancer cells while also boosting the immune system. The second is cemipl…

This study observed 311 adults with advanced kidney cancer who received cabozantinib (a targeted therapy) plus nivolumab (an immunotherapy) as their first treatment. Researchers tracked how long patients lived and how long tumors stayed under control in real-world settings. The g…

This early-stage trial tested a drug called belzutifan in 29 people with advanced clear cell kidney cancer that had worsened after other treatments. The main goal was to check safety and find the right dose. Participants took belzutifan pills daily, and researchers monitored side…

This Phase 3 trial tested whether combining pembrolizumab (an immunotherapy) with epacadostat (a drug that boosts the immune response) works better than standard drugs (sunitinib or pazopanib) for people with advanced kidney cancer that hasn't been treated before. The study enrol…

This trial tested a combination of two drugs—axitinib (a standard kidney cancer drug) and seleniomethionine (a form of selenium)—in 45 adults with advanced clear cell renal cell carcinoma that had spread. The goal was to find the safest dose and see if the combination could shrin…

This study tested a new treatment for people with advanced clear cell kidney cancer that had spread and stopped responding to standard therapies. Six adults received four injections of a radioactive drug (177Lu-PSMA-1) that targets cancer cells. The goal was to check safety and s…

This early-phase study tested two immunotherapy drugs (spartalizumab and canakinumab) given before surgery to 17 people with localized clear cell kidney cancer. The main goal was to see if this approach was safe and did not delay surgery. The study also looked at how the drugs af…

This early-phase study tested a new drug called gevokizumab alongside standard cancer treatments in 167 adults with advanced colorectal, stomach, or kidney cancer that had spread. The goal was to find a safe and active dose and see if the combination could help control the diseas…

This study tested a new drug called ARO-HIF2 in 26 people with advanced clear cell kidney cancer that had gotten worse after other treatments. The main goal was to find a safe dose and check for side effects. This is an early-phase trial, so it focuses on safety and dosing, not y…

This study tested a prediction tool (nomogram) to see if it could forecast how patients with metastatic clear cell renal cell carcinoma respond to the targeted therapy sunitinib. Researchers looked at 45 patients who had their kidney removed and were treated with sunitinib as the…

This completed study looked back at the medical records of 200 patients with advanced clear cell kidney cancer who received Tivozanib as their first treatment. The goal was to see how long patients went without their cancer getting worse and how long they lived overall. The study…